Innovating Works
NMBP-15-2017
Nanotechnologies for imaging cellular transplants and regenerativ...
Specific Challenge:Detection and monitoring of cell and tissue transplants in vivo is of utmost importance for development of clinical cell therapy. Suitable nanotechnology-based imaging approaches with high sensitivity should allow for monitoring of cell viability, engraftment and distribution, also through the use of nanomaterials for cells marking. Appropriate imaging techniques have been developed for application in small animals, but are not available yet for use in preclinical large animal models and patients. In particular, such technologies will represent an important safety measure enabling early detection of cell based therapy.
Sólo fondo perdido 0 €
Europeo
Esta convocatoria está cerrada Esta línea ya está cerrada por lo que no puedes aplicar. Cerró el pasado día 27-10-2016.
Se espera una próxima convocatoria para esta ayuda, aún no está clara la fecha exacta de inicio de convocatoria.
Por suerte, hemos conseguido la lista de proyectos financiados!
Presentación: Consorcio Consorcio: Esta ayuda está diseñada para aplicar a ella en formato consorcio.
Número mínimo de participantes.
Esta ayuda financia Proyectos: Objetivo del proyecto:

Specific Challenge:Detection and monitoring of cell and tissue transplants in vivo is of utmost importance for development of clinical cell therapy. Suitable nanotechnology-based imaging approaches with high sensitivity should allow for monitoring of cell viability, engraftment and distribution, also through the use of nanomaterials for cells marking. Appropriate imaging techniques have been developed for application in small animals, but are not available yet for use in preclinical large animal models and patients. In particular, such technologies will represent an important safety measure enabling early detection of cell based therapy.


Scope:Proposals should focus on the following:

Development of highly sensitive imaging approaches enabling discrimination of living cell and tissue transplants based e.g. on optical imaging, magnetic resonance imaging and / or nuclear medicine techniques; Monitoring should be highly sensitive, in best case allowing for detection of single cells and cell morphologies; Possibility of non-invasive whole body monitoring (magnetic, optical) in large animals; Development of clinically applicable imaging approaches, t... ver más

Specific Challenge:Detection and monitoring of cell and tissue transplants in vivo is of utmost importance for development of clinical cell therapy. Suitable nanotechnology-based imaging approaches with high sensitivity should allow for monitoring of cell viability, engraftment and distribution, also through the use of nanomaterials for cells marking. Appropriate imaging techniques have been developed for application in small animals, but are not available yet for use in preclinical large animal models and patients. In particular, such technologies will represent an important safety measure enabling early detection of cell based therapy.


Scope:Proposals should focus on the following:

Development of highly sensitive imaging approaches enabling discrimination of living cell and tissue transplants based e.g. on optical imaging, magnetic resonance imaging and / or nuclear medicine techniques; Monitoring should be highly sensitive, in best case allowing for detection of single cells and cell morphologies; Possibility of non-invasive whole body monitoring (magnetic, optical) in large animals; Development of clinically applicable imaging approaches, taking into account medical regulatory aspects; Interpretation of the data with theoretical models (to be developed if necessary). As relevant, the proposed activities should address sex and gender specific aspects[1].

Activities are expected to commence at Technology Readiness Levels 3/4 and reach 5/6.

The Commission considers that proposals requesting a contribution from the EU between EUR 5 and 7 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.


Expected Impact: Availability of novel highly sensitive nanotechnology-based imaging approaches allowing for monitoring of survival, engraftment, proliferation, function and whole body distribution of cellular transplants in preclinical large animal models and patients; Imaging technologies facilitating the provision of new regenerative therapies to patients; Opening of a new market sector for imaging equipment and supplies, reinforcement of the European healthcare supply chain and improvement of the competitiveness of the European healthcare sector. Proposals should include a business case and exploitation strategy, as outlined in the Introduction to the LEIT part of this Work Programme.


Cross-cutting Priorities:Gender


[1]See definition of the 'gender dimension approach' in the introduction of this Work Programme part.

ver menos

Temáticas Obligatorias del proyecto: Temática principal: Medical engineering Other medical sciences

Características del consorcio

Ámbito Europeo : La ayuda es de ámbito europeo, puede aplicar a esta linea cualquier empresa que forme parte de la Comunidad Europea.
Tipo y tamaño de organizaciones: El diseño de consorcio necesario para la tramitación de esta ayuda necesita de:

Características del Proyecto

Requisitos de diseño por participante: Duración:
Requisitos técnicos: Specific Challenge:Detection and monitoring of cell and tissue transplants in vivo is of utmost importance for development of clinical cell therapy. Suitable nanotechnology-based imaging approaches with high sensitivity should allow for monitoring of cell viability, engraftment and distribution, also through the use of nanomaterials for cells marking. Appropriate imaging techniques have been developed for application in small animals, but are not available yet for use in preclinical large animal models and patients. In particular, such technologies will represent an important safety measure enabling early detection of cell based therapy. Specific Challenge:Detection and monitoring of cell and tissue transplants in vivo is of utmost importance for development of clinical cell therapy. Suitable nanotechnology-based imaging approaches with high sensitivity should allow for monitoring of cell viability, engraftment and distribution, also through the use of nanomaterials for cells marking. Appropriate imaging techniques have been developed for application in small animals, but are not available yet for use in preclinical large animal models and patients. In particular, such technologies will represent an important safety measure enabling early detection of cell based therapy.
¿Quieres ejemplos? Puedes consultar aquí los últimos proyectos conocidos financiados por esta línea, sus tecnologías, sus presupuestos y sus compañías.
Capítulos financiables: Los capítulos de gastos financiables para esta línea son:
Personnel costs.
Los costes de personal subvencionables cubren las horas de trabajo efectivo de las personas directamente dedicadas a la ejecución de la acción. Los propietarios de pequeñas y medianas empresas que no perciban salario y otras personas físicas que no perciban salario podrán imputar los costes de personal sobre la base de una escala de costes unitarios
Purchase costs.
Los otros costes directos se dividen en los siguientes apartados: Viajes, amortizaciones, equipamiento y otros bienes y servicios. Se financia la amortización de equipos, permitiendo incluir la amortización de equipos adquiridos antes del proyecto si se registra durante su ejecución. En el apartado de otros bienes y servicios se incluyen los diferentes bienes y servicios comprados por los beneficiarios a proveedores externos para poder llevar a cabo sus tareas
Subcontracting costs.
La subcontratación en ayudas europeas no debe tratarse del core de actividades de I+D del proyecto. El contratista debe ser seleccionado por el beneficiario de acuerdo con el principio de mejor relación calidad-precio bajo las condiciones de transparencia e igualdad (en ningún caso consistirá en solicitar menos de 3 ofertas). En el caso de entidades públicas, para la subcontratación se deberán de seguir las leyes que rijan en el país al que pertenezca el contratante
Madurez tecnológica: La tramitación de esta ayuda requiere de un nivel tecnológico mínimo en el proyecto de TRL 5:. Los elementos básicos de la innovación son integrados de manera que la configuración final es similar a su aplicación final, es decir que está listo para ser usado en la simulación de un entorno real. Se mejoran los modelos tanto técnicos como económicos del diseño inicial, se ha identificado adicionalmente aspectos de seguridad, limitaciones ambiéntales y/o regulatorios entre otros. + info.
TRL esperado:

Características de la financiación

Intensidad de la ayuda: Sólo fondo perdido + info
Fondo perdido:
Please read carefully all provisions below before the preparation of your application.
 
LIST OF COUNTRIES and APPLICABLE RULES FOR FUNDING
described in part A of the General Annexes of the General Work Programme.
Note also that a number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon 2020 projects (follow the links to Australia, Brazil, Canada, China, Hong Kong &Macau, India, Japan, Republic of Korea, Mexico, Russia, Taiwan).
 
ELIGIBILITY and ADMISSIBILITY CONDITIONS
described in part B and C of the General Annexes of the General Work Programme.
Proposal page limits and layout: Please refer to Part B of the standard proposal template.
 
EVALUATION
3.1  Evaluation criteria and procedure, scoring and threshold:
The criteria, scoring and threshold are described in General Annex H of the work programme.
The following exceptions apply:
For single-stage and second-stage evaluations, the threshold for the criteria Excellence and Impact will be 4. The overall threshold, applying to the sum of the three individual scores, will be 12.
The procedure for setting a priority order for proposals with the same score is given in General Annex H of the work programme. The following exceptions apply:
Under 3 (a)
Proposals are first ranked...
Please read carefully all provisions below before the preparation of your application.
 
LIST OF COUNTRIES and APPLICABLE RULES FOR FUNDING
described in part A of the General Annexes of the General Work Programme.
Note also that a number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon 2020 projects (follow the links to Australia, Brazil, Canada, China, Hong Kong &Macau, India, Japan, Republic of Korea, Mexico, Russia, Taiwan).
 
ELIGIBILITY and ADMISSIBILITY CONDITIONS
described in part B and C of the General Annexes of the General Work Programme.
Proposal page limits and layout: Please refer to Part B of the standard proposal template.
 
EVALUATION
3.1  Evaluation criteria and procedure, scoring and threshold:
The criteria, scoring and threshold are described in General Annex H of the work programme.
The following exceptions apply:
For single-stage and second-stage evaluations, the threshold for the criteria Excellence and Impact will be 4. The overall threshold, applying to the sum of the three individual scores, will be 12.
The procedure for setting a priority order for proposals with the same score is given in General Annex H of the work programme. The following exceptions apply:
Under 3 (a)
Proposals are first ranked in separate lists according to the topics against which they were submitted (‘topic ranked lists’). When comparing ex aequo proposals from different topics, proposals having a higher position in their respective 'topic ranked list' will be considered to have a higher priority in the overall ranked list.
Under 3 (b)
For all topics and types of action, the prioritisation will be done first on the basis of the score for Impact, and then on that for Excellence.
3.2 Submission and evaluation process: Guide to the submission and evaluation process
    
INDICATIVE TIMETABLE for EVALUATION and GRANT AGREEMENT
Information on the outcome of two-stage evaluation:
      For stage 1: maximum 3 months from the deadline for submission.
      For stage 2: maximum 5 months from the deadline for submission.
Signature of grant agreements: maximum 8 months from the deadline for submission.
 
PROVISIONS, PROPOSAL TEMPLATES and EVALUATION FORMS
for the type of action under this topic
Research and Innovation Action:
Specific provisions and funding rates
Standard proposal template
Standard evaluation form
H2020 General MGA -Multi-Beneficiary
Annotated Grant Agreement
 
ADDITIONAL PROVISIONS
Horizon 2020 budget flexibility
Classified information
Technology readiness levels (TRL) – where a topic description refers to TRL, these definitions apply.
Financial support to Third Parties – where a topic description foresees financial support to Third Parties, these provisions apply.
 
OPEN ACCESS
Open access must be granted to all scientific publications resulting from Horizon 2020 actions.
Where relevant, proposals should also provide information on how the participants will manage the research data generated and/or collected during the project, such as details on what types of data the project will generate, whether and how this data will be exploited or made accessible for verification and re-use, and how it will be curated and preserved.
Open access to research data
The Open Research Data Pilot has been extended to cover all Horizon 2020 topics for which the submission is opened on 26 July 2016 or later. Projects funded under this topic will therefore by default provide open access to the research data they generate, except if they decide to opt-out under the conditions described in annex L of the Work Programme. Projects can opt-out at any stage, that is both before and after the grant signature.
Note that the evaluation phase proposals will not be evaluated more favourably because they plan to open or share their data, and will not be penalised for opting out.
Open research data sharing applies to the data needed to validate the results presented in scientific publications. Additionally, projects can choose to make other data available open access and need to describe their approach in a Data Management Plan.
- Projects need to create a Data Management Plan (DMP), except if they opt-out of making their research data open access. A first version of the DMP must be provided as an early deliverable within six months of the project and should be updated during the project as appropriate. The Commission already provides guidance documents, including a template for DMPs.
- Eligibility of costs: costs related to data management and data sharing are eligible for reimbursement during the project duration.
The legal requirements for projects participating in this pilot are in the article 29.3 of the Model Grant Agreement.
 
ADDITIONAL DOCUMENTS
Legal basis: Horizon 2020 - Regulation of Establishment
Legal basis: Horizon 2020 Rules for Participation
Legal basis: Horizon 2020 Specific Programme
H2020 Work Programme 2016-17: Introduction
H2020 Work Programme 2016-17: Introduction to Leadership in enabling and industrial technologies (LEITs)
H2020 Work Programme 2016-17: Nanotechnologies, advanced materials, advanced manufacturing and processing, biotechnology
H2020 Work Programme 2016-17: Cross-cutting activities (Focus Areas)
H2020 Work Programme 2016-17: Dissemination, Exploitation and Evaluation
H2020 Work Programme 2016-17: General Annexes
 
Garantías:
No exige Garantías
No existen condiciones financieras para el beneficiario.

Información adicional de la convocatoria

Efecto incentivador: Esta ayuda tiene efecto incentivador, por lo que el proyecto no puede haberse iniciado antes de la presentación de la solicitud de ayuda. + info.
Respuesta Organismo: Se calcula que aproximadamente, la respuesta del organismo una vez tramitada la ayuda es de:
Meses de respuesta:
Muy Competitiva:
No Competitiva Competitiva Muy Competitiva
No conocemos el presupuesto total de la línea
Minimis: Esta línea de financiación NO considera una “ayuda de minimis”. Puedes consultar la normativa aquí.

Otras ventajas

Sello PYME: Tramitar esta ayuda con éxito permite conseguir el sello de calidad de “sello pyme innovadora”. Que permite ciertas ventajas fiscales.
H2020-NMBP-2016-2017 Nanotechnologies for imaging cellular transplants and regenerative processes in vivo Specific Challenge:Detection and monitoring of cell and tissue transplants in vivo is of utmost importance for development of clinical cell...
Sin info.
NMBP-38-2020 Citizens and industrial technologies (CSA)
en consorcio: Specific Challenge:Key enabling technologies[1], in addition to their importance to industry, provide new solutions to global challenges and...
Cerrada hace 5 años | Próxima convocatoria prevista para el mes de
NMBP-36-2020 Monitoring and safety of transport infrastructures (CSA)
en consorcio: Specific Challenge:Bridges can be particularly vulnerable elements of transport infrastructures. In particular, road bridges may be approach...
Cerrada hace 5 años | Próxima convocatoria prevista para el mes de
NMBP-37-2020 Incentivising newcomers (CSA)
en consorcio: Specific Challenge:The essential criteria for selecting projects under Horizon 2020 are excellence, impact and implementation. This requires...
Cerrada hace 5 años | Próxima convocatoria prevista para el mes de
DT-NMBP-39-2020 Towards Standardised Documentation of Data through taxonomies and ontologies (CSA)
en consorcio: Specific Challenge:Standardised data documentation with metadata based on an agreed ontology[1] across the domains covered by this work prog...
Cerrada hace 5 años | Próxima convocatoria prevista para el mes de
CE-NMBP-41-2020 ERA-NET on materials, supporting the circular economy and Sustainable Development Goals
en consorcio: Specific Challenge:Maintaining Europe’s position in research related to materials science and engineering requires concentrated action on co...
Cerrada hace 5 años | Próxima convocatoria prevista para el mes de